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I. OVERVIEW 
Well I’m sure you’re wondering, what is the success rate? Roca Labs’ 
Formula is scientifically proven to have a 90% success rate. It will always 
achieve a gastric bypass effect by physically occupying your stomach, leaving 
only 20% available space for 10-16 hours. You’ll eat 50% less, and can spare 
your body as much as 2,000 unnecessary calories a day without feeling any 
urge to overeat. That equals 15 pounds a month. 
 
“What is the Success Rate?” video on RocaLabs.com, Dkt. 6-2, Att. V21 
 
Defendants sold Roca Labs “Formula” dietary supplements to more than 50,000 
consumers across the United States from 2009 through 2015. Using search advertising, 
websites, and online videos, they claimed that the Formula worked by substantially limiting a 
user’s stomach capacity. Purportedly comparable to gastric bypass surgery, but without the 
risk and expense, this effect supposedly caused dramatic weight loss and was scientifically 
proven to have a ninety-percent success rate. What customers who paid hundreds of dollars 
for this supposed “gastric bypass alternative” actually got were common dietary fibers that 
have been shown to be of little, if any, help in weight loss. The undisputed facts of this case 
show that Defendants leveraged these core deceptions, and several other deceptive and unfair 
practices, to take in more than $25 million in violation of the FTC Act. Accordingly, the FTC 
seeks summary judgment and injunctive relief on all counts against all defendants, and 
$25,246,000 in monetary relief from Defendant Don Juravin and the corporate defendants. 
                                                 
1 “PX” citations refer to Plaintiff’s Exhibits 1-26 hereto. Citations of the form PX#-#, #(____) denote 
the starting page or pages of ranges in which cited transcript pages or Requests for Admissions 
appear. Citations of the form PX#-## generally refer to the first pages of cited deposition exhibits, 
unless the context indicates that the reference is to a specific exhibit page.  
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II. THE PARTIES 
The FTC is an independent agency of the United States Government created by 
statute. 15 U.S.C. §§ 41-58. The FTC enforces Section 5(a) of the FTC Act, 15 U.S.C. § 
45(a), which prohibits unfair or deceptive acts or practices in or affecting commerce. The 
FTC also enforces Section 12 of the FTC Act, 15 U.S.C. § 52, which prohibits false 
advertisements for food, drugs, devices, services, or cosmetics in or affecting commerce. 
From 2009 through the present, Defendant Don Juravin (“Juravin”) has had authority 
and control over all five corporate defendants: Roca Labs, Inc. (“RLI”), Roca Labs 
Nutraceutical USA, Inc. (“RLN”), Must Cure Obesity, Co. (“MCO”), Juravin, Incorporated 
(“JI”), and Zero Calorie Labs, Inc. (“ZCL”) (collectively, “Corporate Defendants”). 2 Juravin 
owns MCO and JI and has been an officer of RLI and RLN, sometimes claiming ownership 
of RLN. He controlled the advertising of Roca Labs products, and directed and controlled the 
challenged practices. Defendant George Whiting (“Whiting”) owns and has been an officer 
                                                 
2 The FTC’s evidence is presented in exhibits that include advertising, deposition transcripts and 
documents, expert reports, and discovery responses. Defendants did not answer or object to the FTC’s 
Requests for Admissions (“RFA”), which are thus deemed admitted. Fed. R. Civ. P. 36(a)(3). See 
PX22 ¶¶2-12. Because the RFAs to Juravin and the Corporate Defendants are identical, citations to 
the RFA served on defendant RLI refer also to the identically numbered RFAs for Juravin and the 
other Corporate Defendants in PX24. PX22 ¶¶2, 4. The FTC also relies on cited declarations and 
exhibits filed previously in this case. Defendants’ Answers on the points cited herein are substantially 
identical. References to Juravin’s Answer, Dkt. 58, refer also to the same statements at the same 
paragraph numbers in Dkt. 59-Dkt. 64.  
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of RLI, RLN, and ZCL. The Corporate Defendants are all Florida entities3 that operated as a 
common enterprise to sell Roca Labs products through deceptive and unfair practices.  
III. DEFENDANTS’ DECEPTIVE AND UNFAIR BUSINESS PRACTICES 
A. Defendants’ Advertising and Business Practices 
1. Weight Loss Claims 
Defendants’ main product since 2009 has been Roca Labs “Formula” dietary 
supplements4 (a/k/a “Gastric Bypass NO Surgery,” and “Gastric Bypass Alternative”). Dkt. 
58 ¶¶15, 19. PX6-21(31:5-13); PX6-29(70:1-11); PX6-217 ¶¶4-5; PX6-8(44:7-18); PX6-107, 
116; PX24-15, 18(117, 145-146). Defendants relied primarily on Google, Bing, Yahoo, and 
Facebook ads to direct consumers to their websites selling the Formula. PX24-16, 18-19(130-
134, 150-151, 156); PX6-58(187:23-189:17); PX6-5(22:15-23:9; 29:24-30:19; 31:14-32:1); 
PX6-13(56:22-57:8); PX9-23(171:11-172:20). Defendants typically targeted overweight and 
obese consumers by delivering ads when consumers ran searches for terms relating to 
bariatric surgery.5 PX6-49(153:3-24); PX6-73(398:4-402:9). Their search ads often 
mentioned “Extreme Weight Loss” and a “90% Success Rate,” favorably comparing their 
                                                 
3 The Corporate Defendants each have a place of business in this district. Dkt. 58 ¶¶3, 6-10 Their 
specific roles are set forth in Section III.E, below.  
 
4 The Formula’s ingredients are Beta Glucan, Guar Gum, Xanthan Gum, Konjac, Inulin, Natural 
Color, Sucralose, Vitamin C, B6, B12, Fruit Flavor. PX24-15(118). Roca Labs Anti-Cravings 
(ingredients of which are Beta Glucan and Fibersol®-2 [PX24-15(119)]) was a companion product. 
 
5 Bariatric surgical procedures, including gastric bypass surgery, cause weight loss by restricting the 
amount of food the stomach can hold, reducing absorption of nutrients, or a combination of both. See 
PX3-12 ¶20.  
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products to bariatric surgery in price and outcome. PX24-18(154), PX24-85(641-42); PX10-
25(151:6-152:2); PX10-189; PX6-36(98:2-99:13; 102:11-103:17); PX6-383, PX6-419; PX6-
460); PX6- 39(112:7-24); PX6-513; PX6-40(116:17-117:14). Defendants spent 
approximately $12 million on advertising from 2010 to 2015. PX7-8 (447:1-4).6  
Defendants claimed the Formula was for consumers who wished to lose fifty or more 
pounds, PX6-29(70:1-11); DJ PX6-217 ¶4, and typically sold a three- to four-month supply 
of Formula for $480. PX24-15(120-122). They distinguished themselves from other sellers 
and justified the price with a seemingly simple but remarkable mechanism of action. On their 
websites, RocaLabs.com and mini-gastric-bypass.me (“Roca Labs sites”), through which the 
substantial majority of their sales were generated [Dkt. 58 ¶20; PX13-10], Defendants 
claimed that taking Roca Labs Formula will restrict a user’s stomach volume, creating a 
“gastric bypass effect” without the risks and expense of surgery. Dkt. 6-7, PageID 194, 198-
99, 271, 277, 300[V1]; PX24-64, 66, 67(531-32, 545-46, 552); see generally Dkt. 6-7, 
PageID 193-272; PX24-64(531-47). Defendants claimed the Formula leaves only twenty 
percent of the stomach available for food intake for approximately ten to sixteen hours and 
reduces cravings. As a result, it supposedly caused dramatic weight loss, including 21 pounds 
per month, and 100 pounds in seven to ten months. The ads promised that the supplements 
would force users to eat less without diet restrictions, causing immediate weight loss:   
                                                 
6 Different Corporate Defendants paid for online ads at different times, but all to benefit the same 
product. PX6-25(53:20-54:20; 56:11-19; 59:10-14; 60:13-22); PX24-18(152-53). 
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How does it work? 
NEW: a dose of the Roca Labs formula is mixed with water and turns into 350cc 
stomach-sized red mixture. Successful users report that when consumed in the 
morning, the Regimen creates a feeling akin to limiting functional stomach volume 
for the duration of your day. This result is achieved without surgical procedures, 
including cutting parts of the digestive system. 
 
With limited stomach volume, you eat much less. . . .  Bariatric surgery does not 
eliminate your cravings; Roca Labs Anti-Cravings can reduce your urge for sweets 
and snacks and other foods that prevent your weight loss success enhancing the loss 
of an additional 5 to 8 pounds a month! Learn more 
 
Dkt. 6-2, PageID 198-99; PX24-64(532). See also Dkt. 48 ¶26 (image) and Dkt. 58 ¶26. 
How much weight can I expect to lose?   
The weight loss can be immediate with the Roca Labs’ regimen, just as if you had 
undergone a bariatric surgery, and within a few days the cravings should be 
diminished significantly. Depending on your commitment to the recommended rules 
for suggested use, a loss of 21 lb a month is possible; however, realistically, it may 
take 7 to 10 months to lose 100 lb. 
 
Dkt. 6-2, PageID 198-99; PX24-64(532). See also Dkt. 6-2, PageID 209; PX24-64(534); Dkt. 
6-2, PageID 300[V3]; PX24-67(554). 
No Menus, No Diet Restrictions 
Unlike weight loss pills or diet programs, Roca Labs® Formula does not require a 
strict menu or calorie restrictions.  It practically FORCES you to eat HALF the 
food you ate before, so you will automatically lose weight without having to keep 
track of every calorie you consume.  
 
Dkt. 6-2, PageID 206; PX24-64(533); see also PX26-4; PX24-73(601).  
The sites also featured videos of persons in lab coats reiterating the “gastric bypass 
effect,” a “scientifically proven” ninety-percent success rate, rapid and substantial weight 
loss, and effectiveness comparable to gastric bypass surgery:  
Well I’m sure you’re wondering, what is the success rate?  Roca Labs’ 
Formula is scientifically proven to have a 90% success rate.  It will always 
achieve a gastric bypass effect by physically occupying your stomach, leaving 
only 20% available space for 10-16 hours.  You’ll eat 50% less, and can spare 
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your body as much as 2,000 unnecessary calories a day without feeling any 
urge to overeat.  That equals 15 pounds a month. 
 
Dkt. 6-2, PageID 300[V3]; PX24-67(553); see also PX24-67(552-55); PageID 300[V1-V4]; 
PX26-1; PX24-72(594); Dkt. 48 ¶29 (image) and Dkt. 58 ¶29; Dkt. 6-2, PageID 240-42; 
PX24-65(540); Dkt. 6-2, PageID 276-79; PX24-65(546). 
Defendants did not limit their claims just to overweight adults. The sites also touted 
the efficacy and safety of their products for children as young as six. Defendants claimed that 
“[m]any children have used the Formula successfully and safely,” with the same “gastric 
bypass effect,” stating that it was “safe for children ages 6 and up with a parent’s supervision.  
It works by physically expanding in the stomach to leave only a very limited space available 
for food intake. Throughout the day, your child will eat HALF the food they used to, without 
hunger.” Dkt. 6-2, PageID 215; see also PageID 220-21; PX24-64(535). 
Defendants used the cachet of medicine to amplify their efficacy claims. Their 
webpages titled “Letter to your doctor” [PX24-64(536); Dkt. 6-2, PageID 225-28] and 
“Medical Evidence for Success” [Dkt. 6-2, PageID 281-89; PX24-66(547)] feature a 
physician, Ross Finesmith, extolling the products’ weight-loss benefits supposedly based on 
his patients’ and his own use.7 The pages refer to “multiple medical studies” or “medical and 
scientific research” that supposedly prove the weight-loss benefits of the Formula. Dkt. 6-2, 
PageID 225, 283. Indeed, nearly every aspect of the websites’ text and images—from the 
                                                 
7 Juravin even rewrote what Finesmith had written without asking him, such as the claim that 
Finesmith’s patients successfully tried Roca Labs products, which Finesmith testified was false. 
PX24-37(324-25, 329-331); PX24-40(343-48, 351-53); PX11-13(92:22-93:6); PX11-19(132:15-
134:2, 134:13-24, 135:10-136:1). 
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name Roca “Labs,” photos of lab workers and caduceus symbols, to references to FDA 
approval of an ingredient, health insurance, and a (non-functioning) Doctor portal—fortify 
the net impression that their weight-loss claims are scientifically proven. See, e.g., Dkt. 6-2, 
PageID 194-96, 198, 201-02, 215, 248, 253, 271-75; 300[V4 at 2:04]; PX24-64(531-32, 
535), PX24-65(542-43, 545-55); PX10-23(143:9-144:2), PX10-182; PX24-25(209-11).  
Defendants made these same basic claims in their videos and websites – in varying 
layouts and formats, sometimes with different stock photos, but always with the same actors 
in lab coats – from at least the start of 2011 until the FTC sued them at the end of September 
2015. PX10-33(200:1-4; 201:8-202:2); PX10-22(133:7-135:8), PX10-181; PX6-43(125:23-
126:12); PX6-705, 706; PX10-30(186:4-25; 191:13-192:1); PX10-29(165:19-166:12; 167:9-
13); PX10-199; PX10-201; PX6-46(141:1-18); PX6-718; PX2 (The Importance of Drinking 
Water); PX11-17(117:25-120:9; 122:5-9); PX10-180; PX10-21(131:13-132:24); PX10-185; 
PX10-23( 143:4-144:22; 145:17-146:7).8 Defendants have recently claimed that the 
supplements were an incidental part of a larger “program,” requiring significant dietary 
restrictions and exercise, as well as personal “coaching,” PX5-3, 13(22:5-14; 140:9-24). The 
ads belie this, as does the understanding of key Roca Labs personnel. PX10-7(35:8-16); 
PX11-6(22:6-13). The core marketing message, reinforced through express claims, images of 
                                                 
8 See also PX26-2; PX26-5; PX26-127; PX26-40, 45, 48, 53, 55, 58, 63, 66, 69, 71, 79, 71, 77, 79, 84, 
88, 95; PX26-11, 13, 16, 19, 28, 31, 35, 38; PX26-1, 3, 4, 9, 10; PX24-23(189-196); PX24-68(559-
592, 594, 596, 601, 607, 613); PX 25-10; PX24-84(635-636). Videos cited in RFAs 189-96, 596, 607, 
and 613are substantially identical to the videos at Dkt. 6-2, PageID 300 [V1-V4] referred to in the 
record by other file names. PX1 ¶6. 
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stomachs “filled” with the supplements, and the product name “Gastric Bypass No Surgery,” 
was that the supplements were the primary cause of the weight loss. 
2. Endorsements 
Defendants also promoted their product through apparently neutral or unbiased 
referrals. For example, Defendants operated GastricBypass.me [PX24-25(203); PX10-
26(154:18-155:20); PX10-191], a purportedly independent website providing information 
about bariatric surgery and “alternatives to surgery.” Juravin created this site (to “educate and 
scare people about” gastric bypass surgery), and Defendants sometimes directed traffic to it 
via search advertising. PX6-54(174:9-177:4); PX6-832; PX6-46(144:19-22); PX6-816. It 
included lengthy “Surgery Failures” and “Surgical Alternatives” pages. Defendants portrayed 
this site as an objective resource for consumers seeking information on gastric bypass 
surgery. Dkt. 6-2, PageID293-97; PX24-63, 66(525, 549-50). In fact, Roca Labs’ products 
are the only “alternative” the site favorably discusses. The site’s purported “panel of experts” 
stated that Roca Labs’ weight-loss claims are trustworthy “for the most part,” and that the 
Roca Labs “[m]edical claims are correct.” Dkt. 6-2, PageID295-97. There was no disclosure 
on the GastricBypass.me site that it was affiliated with RLI. PX24-25(204).  
Defendants promoted their products through videos of purported satisfied users.9 For 
example, one video shows a woman claiming to have lost significant weight using the 
Formula. She was actually a paid actor who did not use it, but there is no disclosure in the 
                                                 
9 Defendants also posted advertising videos on YouTube and Vimeo channels whose content Juravin 
controlled. PX24-20, 24(160-161; 197-202); PX10-30(186:21-187:15; 188:10-15). Defendants falsely 
claimed to have 100,000 video testimonialists. PX24-20, 61(162-164; 506). 
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video. PX2 (004548), PX24-21(167-68); Dkt. 6-2, PageID 237. These videos were on the 
RocaLabs.com site or YouTube channel from 2011-15. PX10-31 (192:2-193:4; 200:5-201:7; 
203:12-204:9; 207:14-208:5; 209:20-211:14); PX13-12. 
Some of the “satisfied consumers” in the videos were paid independent contractors 
who were working for Defendants when they made their videos. One video [PX2 (004550)] 
shows “Carla,” who worked for Defendants when the video was made in about 2013. PX10-
32 (193:11-194:10); PX12-15(168:11-169:20). Another [PX2 (004559)] shows “Roxie,” who 
was working for Defendants when her video was made. PX12-8(36:3-12; 39:5-25).10 These 
videos were accessible to prospective purchasers of Roca Labs products via RocaLabs.com 
in 2014 and 2015. PX24-73(604; 606); Dkt. 6-2, PageID 194, 237.  
Also at Juravin’s direction, Defendants had their agents create blogs [PX25-20; 
PX24-85(645-48); PX10-39(238:24-239:23); PX10-212; PX24-23(185-86)], make 
embellished or fictitious forum posts or reviews [PX24-22, 41(179-188, 349-53); PX11-
19(130:2-134:24); PX11-24; PX6-64, 65(237:16-238:8; 238:16-17; 281:24-282:24], and 
comment on Roca Labs Facebook ads [PX10-37(226:15-227:8); PX10-211; PX12-
12(138:13-140:10)], all to promote the products and direct traffic to Defendants’ websites.  
3. Privacy Promise  
Defendants strongly implied that consumers who decide to buy Roca Labs products 
must meet stringent medical criteria, by requiring detailed personal information to be 
“evaluated” prior to purchase. This process bolstered the impression that Defendants’ 
                                                 
10 PX2 (004559) and the exhibit shown at Hensley’s deposition are substantially identical. PX1 ¶6. 
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overpriced fiber supplement is a medically-sanctioned weight-loss intervention. Indeed, the 
site’s order page was titled “Qualify & Order” and has videos about the “qualification” 
process. It stated that the questionnaire “is designed to filter out those with limited chance of 
being successful and who are absolutely not suited to use the STRONG Formula or handle 
the regimen successfully.” PX6-49(154:14-156:9); PX6-821. To purchase the products, 
consumers entered personal health information through the “Qualify & Order” pages, 
including on a “Questionnaire” or “Health Application” form. Dkt. 58 ¶43; PX24-26(215, 
217-18). The “Qualify & Order” pages stated that information consumers provided will be 
kept confidential and will not be shared. PX24-26(216). Similar statements appeared in the 
purchasing process from December 2010 through the time this lawsuit was filed. PX10-
5(19:24-20:5; 25:20-26:1); PX10-14(95:14-24); PX10-40; PX6-49(156:10-157:3); PX6-821; 
PX10-29(166:1-12; 166:25-167:4; 167:11-168:7); PX10-204.11 
Purchasers responded to the Questionnaire (PX24-26(219); PX6-49(154:14-155:17); 
PX6-821) by entering their full name, gender, age, weight, height, and insurance carrier. 
PX24-26(218); PX6-50(157:4-13); PX6-821. Consumers were asked about issues with 
cholesterol, high blood pressure, diabetes, and digestion, [PX24-26(220); PX6-50(157:23-
                                                 
11 Between late 2012 and 2014, the RocaLabs.com site had a privacy policy stating: “Our Policy is 
SIMPLE Just like doctor-patient confidentiality, Roca Labs does NOT share your information with 
any third party companies or advertisers in any way. . . . [I]nformation collected is meant only to 
assist you to achieve your weight-loss goal. . . .” PX10-27(158:18-159:7; 162:16-163:19); PX10-197. 
A “Summary” document inserted in product packages stated that RLI “will not share your private 
information with anyone.” PX24-27(224-25), Dkt. 6-3, PageID 340 ¶10, PageID 367. 
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158:6); PX6-824], and weight-related psychological issues, including past weight-loss 
failures, depression, and binge eating. PX24-26(221); PX6-50(158:7-18); PX6-825.12  
Near the end of the form, prospective purchasers were asked to state why they were 
“truly committed” to losing weight “this time around,” and prompted to agree with the 
statement that “fat is unhealthy and ugly, and I am going to fight and change it” before 
proceeding. PX6-50(158:22-159:19); PX6-826. Purchasers gave personal, emotional 
responses, such as:  “Yes as this weight is taking potentially fatal toll on my life”; and “Yes, I 
want to be here for my son. I want to live.” PX10-16(103:6-108:19); PX10-109, 121. 
4.  “Discount” Pricing 
RLI predominantly advertised that a “Basic” package of Roca Labs products, for “Up 
to 80 lbs to lose,” costs $480 (in a single payment) for purchasers with “valid health 
insurance.” PX24-15(122)13 Defendants frequently stated this price in:  search ads [PX6-
41(117:15-25); PX6-82, 83; PX6-39(112:7-24; 114:18–115:5); PX6-513; Dkt. 6-3, PageID 
339 ¶8, PageID 343-344]; display ads served through Google and Bing [PX6-38(106:10-16; 
110:10-23; 115:6-24); PX6-513; PX13-8]; and Facebook ads [PX6-36(98:2–99:19; 102:11-
22); PX6-386; PX6-419; PX13-8]. This price was advertised on RLI’s websites from 2012 
through 2015. PX6-43(126:13-127:7; 129:12-24; 129:25-130:14; 131:12-132:4; 140:17-
141:18; 141:23-142:6; 142:12-16; 143:14-144:11); PX6-707, 710, 714, 716, 719, 721, 736, 
                                                 
12 Much of the information customers had to enter was irrelevant to whether they “qualified” to buy 
the Formula. PX10-11(84:23-86:18; 89:4-91:19; 95:14-96:23); PX11-9, 12(59:8-60:4; 70:16-72:20). 
 
13 Prices could be several hundred dollars more, depending on the quantity ordered, and whether the 
purchaser said they had health insurance. PX24-25(205-208, 212-214). 
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738, 741, 749; 756, 805. At the bottom of the RocaLabs.com product selection screen, just 
above the “Submit” button, was an unchecked box next to the statement, “I have checked and 
do not have any medical reason that can prevent me from using the Roca Labs Gastric 
Bypass Alternative procedure and I have read and agree to the terms, privacy and money 
back reward / return policy.” Purchasers were not required to review the Terms and 
Conditions before checking the box and clicking “Submit.” Dkt. 6-3, PageID 339 ¶8, PageID 
361-364; PX6-48(152:14-17; 160:18–161:4; 161:15-162:5); PX6-819; PX7-26(584:6-585:5). 
Purchasers only learned that they had supposedly “agreed” to a purported “discount” 
when RLI sent them a two-page, large-print “Summary” of the Terms with their orders, 
which stated: 
Discount Policy.  We believe in our customers and that word of mouth is the 
best promotion. We are here to help you.  You were given a discount off the 
unsubsidized price of $1580 in exchange for your agreement to promote our 
products . . ..  As part of this endorsement you also agree not to write any 
negative reviews about RLN or our products. In the event that you do not 
honor this agreement, you may owe immediately the full price of $1,580.  
 
PX24-30(252, 253); Dkt. 58 ¶53.14 Similarly, a “Thanks for purchasing” package insert 
warned purchasers that “[t]here are NO returns or refunds as stated on 
RocaLabs.com/Terms,” and that consumers who dispute or fail to pay monthly installments 
face possible litigation and significant monetary damages:  
Payments can NOT be cancelled or disputed as this may result in legal action 
against you in Florida where you may need to hire an attorney and may face 
charges in excess of $3,500. . . .  Our Marketing Dept. subsidized your 
                                                 
14  Defendants’ shipments to customers included written package inserts that contained this statement 
in 2014. PX6-52(166:12-24; 167:14–170:11); PX6-830; Dkt. 6-3, PageID 338-340 and 366-367.  
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purchase in return for your commitment to lose weight and post positive 
feedback.  As agreed, you will owe the unsubsidized price of $1,580 if you 
breach the Terms. 
 
Dkt. 6-3, PageID 340 ¶10, 366.15 RLI (via their lawyers) threatened complaining purchasers 
who sought refunds that their “discounts” would be revoked and they would owe the “full” 
price of the Roca Labs’ products. PX24-32(265); PX6-29(70:3-11); PX6-287, 290, 292. 
5. Threats and Lawsuits Based on Gag Clause in Terms and 
Conditions 
 
Only after Defendants shipped the products did consumers learn of the onerous terms, 
both physical and financial, of the costly “procedure,” which might lead them to want to 
complain publicly. PX24-27(227-235). The “Roca Labs Procedure Rules & Diet” enclosure 
shipped with the products contradicted the advertised message of “automatic” weight loss:  it 
turns out users had to stick to a nine-hour “Limited Eating Interval,” drink six half-liter 
bottles of water per day to “maintain the gastric bypass effect,” and exercise at least thirty 
minutes five or more times per week. Dkt. 6-3, PageID 340 ¶10, 370-71; Dkt. 6-4, PageID 
372. But many customers who shared negative comments about their experience faced legal 
threats and even lawsuits alleging that they had breached non-disparagement provisions of 
Defendants’ Terms and Conditions.  
                                                 
15 RLI’s pre- December 2014 Terms included legal sanctions for breach, including paying the 
purported full product price. PX24-29(244). The Terms used between 2011 and 2014 consistently 
represented that the price purchasers were actually being charged was a “conditional,” “discounted,” 
or “subsidized” price being charged in exchange for agreement to non-disparagement and other 
provisions, and that the “full price” was $1,580. PX24-29(246); PX10-16(101:3-13); PX10-66; PX6-
33(87:18-88:23); PX6-329; PX6-32(81:3-24); PX6-319; PX10-15(99:13-23; 100:13-22); PX10-49; 
PX6-29(70:3-11); PX6-139, 140, 181; PX6-34(91:21-92:13); PX6-343; PX10-16(101:14-21); PX10-
80; PX6-34(92:14-93:3); PX6-357; PX6-10(101:25-102:7); PX10-94; PX6-35(93:4-8); PX6-372. 
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These gag clauses, which required customers to agree not to publicly disparage Roca 
Labs, its products, or its employees – regardless of the purchasers’ outcomes – were in 
Defendants’ Terms from 2011 until the FTC filed this case. PX24-28, 63(236-37, 240, 243, 
248-51, 526-29); PX24-67, 77(557-58, 629); Dkt. 58 ¶¶49-50, 52; PX6-32(81:3-24); PX10-
15(99:13-23; 100:13-22); PX10-49; PX10-16(101:3-13); PX10-66; PX6-319; PX6-33 
(87:18-88:23); PX6-329; PX6-34(91:21-92:13); PX6-343; PX6-34(92:14-93:3); PX6-357; 
PX6-35(93:4-8); PX6-371.16 A May 2015 version, for example, bans negative statements, 
punishable by having to pay the “full price” for the products and other legal remedies:  
You agree that regardless of your personal experience with RL, you will not 
disparage RL and/or any of its employees, products or services.  This means 
that you will not speak, publish, cause to be published, print, review, blog, or 
otherwise write negatively about RL, or its products or employees in any way.  
This encompasses all forms of media, including and especially the internet.  
This paragraph is to protect RL and its current and future customers from the 
harm of libelous or slanderous content in any form, and thus, your acceptance 
of the [Terms] prohibits you from taking any action that negatively impacts 
RL, its reputation, products, services, management, or employees.  We make 
it clear that RL and its Regimen may not be for everyone, and in that regard, 
the foregoing clause is meant to prevent “one person from ruining it for 
everyone.”  Should any customer violate this provision, as determined by RL 
in its sole discretion, you will be provided with seventy-two (72) hours to 
retract the content in question.  If the content remains, RL would be obliged to 
seek all legal remedies to protect its name, products, current customers, and 
future customers. 
 
If you breach this Agreement, as determined by RL in its sole discretion, all 
discounts will be waived and you agree to pay the full price for your product.  
In addition, we retain all legal rights and remedies against the breaching 
customer for breach of contract and any other appropriate causes of action. 
 
                                                 
16 Defendants sent similar gag clause warnings in post-purchase emails and package inserts at various 
times since 2011. PX14 ¶9, PX14-10; PX26-18; PX24-77(630); PX16 ¶9. 
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Dkt. 6-2, PageID 263-64; PX24-65(544).  
  Based on such terms, Defendants threatened legal action against dissatisfied 
consumers who said they would complain, or who did complain, to the Better Business 
Bureau (“BBB”) or said that they planned to post negative comments on the internet. Dkt. 58 
¶54; PX24-31(254, 266); Dkt. 6-14 ¶¶12-14, 17; Dkt. 6-15 ¶12; PX14 ¶¶22-24; PX14-47; 
PX15 ¶11; PX16 ¶¶12-13; PX17 ¶14; PX18 ¶¶12-15; PX18-128; PX19 ¶¶8, 11. Defendants 
accused consumers who sought refunds of attempted “extortion,” and even threatened 
criminal charges. PX24-31(255-263); Dkt. 58 ¶54; Dkt. 6-14, PageID 858-59 ¶¶ 13-14, 861-
65; PX21 ¶¶12-13. For example, Defendants lobbed a variety of legal threats at a customer 
who blogged about her negative experience with Defendants’ products and return policy. The 
blog host shut it down after notifying her that Roca Labs threatened it with a lawsuit about 
her posts. PX24-32(267); Dkt. 6-14, PageID 859 ¶18. Despite Defendants’ attempts to stifle 
criticism, more than 100 consumers submitted complaints about Roca Labs to the BBB or the 
FTC in the years leading up to this lawsuit, including approximately twenty complaints 
specifically related to Defendants’ legal threats, or to the negative comment prohibition. Dkt. 
6-7, PageID 669, ¶4. 
Juravin invented his own definitions of legal terms to justify his position that any 
negative comment warrants threats of legal action. He testified that if consumers did not use 
the Formula for the six weeks and follow his draconian “Rules” and “Instructions,” their 
comments were “false.” PX6-26(57:9-58:16); PX7-21(554:14-558:6). He also believes that 
consumers who request a refund and say they will complain to authorities or write negative 
comments are committing “extortion” and “slander”:  
Case 8:15-cv-02231-MSS-TBM   Document 141   Filed 03/24/17   Page 22 of 53 PageID 2959
 16 
 
[I]f somebody will say, if you don’t give me refund on my money. If you don’t – for 
example, I don't want to make a payment.  And if I have to make the payment, I will 
report to the BBB. That’s an extortion. . . . If somebody says, if you don’t give me – if 
you don’t send it – asking some benefit or I will write negative about you, that’s also 
that’s a slander.   
 
PX6-67(297:20-298:15). See also PX6-66(295:6-299:7); PX6-855; PX13 at 10. Defendants 
sued at least four customers for violating the gag clause, among other things. PX24-32(268); 
PX6-30(74:2-77:10); PX6-226, 241, 246, 251; PX10-19(124:2-7; 125:8-20); PX10-129; Dkt 
6-3, PageID 341 ¶11; Dkt. 6-5, PageID 523-73, 579-641.17  
B. Consumer Harm 
 Between 2009 and September 2015, between 50,000 and 60,000 customers purchased 
from the RocaLabs.com website. PX6-71(390:3-11). Defendants’ total gross receipts for 
2011 through September 2015 were more than $25 million for sales of Roca Labs products. 
PX24-16(125-127, 129); PX9-23(169:9-171:3); PX6-4, 7(14:21-15:9; 34:9-36:23). 
C. Defendants’ Advertising Was Deceptive 
1. Defendants’ Weight Loss Claims Were Unsubstantiated and False 
Defendants’ advertising (Section III.A.1, above) made express claims that:  (i) use of 
Roca Labs products enables the user to reduce food intake by fifty percent and to lose 
substantial amounts of weight quickly, including as much as 21 pounds in one month, and as 
much as 100 pounds in seven to ten months; (ii) ninety percent of users of Roca Labs 
products will lose substantial amounts of weight; (iii) Roca Labs products are comparable or 
superior to bariatric surgery in providing weight-loss benefits; (iv) Roca Labs products are 
                                                 
17 Defendant RLI also sued the owners of a website hosting negative reviews about Roca Labs for 
allegedly inducing RLI customers to violate the gag clause and tortiously interfering with prospective 
consumers. Dkt. 58 ¶55; PX6-29(70:1-11); PX6-136.  
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safe and effective for weight loss in children as young as six years old; and (v) the ninety 
percent success rate is scientifically proven.  
Defendants had no competent and reliable scientific evidence to support any of these 
claims.18 The FTC’s expert, Dr. Steven Heymsfield, reviewed material on the Roca Labs 
products and ingredients, and other scientific literature.19 He found no scientific basis for the 
challenged claims. PX3-4, 42 ¶¶ 7, 8, 93, 94. Defendants’ expert, Dr. Jay Hoffman, did not 
even evaluate whether the challenged claims were substantiated; thus, the FTC’s evidence on 
this crucial point is unrebutted. PX5-5 (30:24-32:23; 35:11-19; 36:7-37:20).20  
 Dr. Heymsfield opines, and Defendants admit, that to substantiate their weight loss 
and “scientifically proven” claims, experts in the field of weight loss and obesity would 
require well-designed and properly conducted clinical trials on the Roca Labs products 
themselves. PX3-15 ¶ 22; PX24-51(381-393).21 Defendants’ own expert agreed that placebo-
controlled human studies are needed to establish causation of weight loss in humans. PX5-8 
                                                 
18 Defendants claimed to have substantiation, specifically:  published clinical studies and articles; 
doctor recommendations; clinical studies for product materials; and “experience with over 80,000 
users.” PX13-4. 
 
19 Dr. Heymsfield has conducted numerous weight loss studies over the past 30 years and is an expert 
in obesity treatment and weight loss. PX3-3 ¶¶1-5. PX24-53. 
 
20 Dr. Hoffman would only opine that significant weight loss was “possible” if, and only if, an 
individual adhered to a strict 1200-calorie-a-day-diet, regardless of whether they used the Roca Labs 
products, which is not a claim at issue in this case.  
 
21 Dr. Ross Finesmith, the primary medical advisor to Roca Labs for its weight loss claims, also 
agreed that a double-blind placebo-controlled clinical trial was needed on the Roca Labs products to 
determine efficacy, and told Juravin so. PX11-10(64:4-66:3, 66:24-67:8). 
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(44:15-18, 47:17-50:9). Furthermore, according to both Dr. Heymsfield and Dr. Hoffman, 
clinical trials on the individual ingredients in the products—as opposed to trials on the 
products themselves—cannot establish efficacy for the Roca Labs combination products; to 
determine efficacy for a product with multiple ingredients, Roca Labs would need a study 
that tests the combination. PX13-15 ¶24; PX5-9(47:17-48:13); PX5-11(65:22-67:2; 69:2-13). 
 Defendants do not possess any study that substantiates their claims. They had one 
inadequate clinical study on the Roca Labs products themselves, the Clinical Study Report by 
the Center for Applied Health Sciences (“CAHS”). PX24-42(360). That study was completed 
in September 2015—years after Defendants had started making claims. As Dr. Heymsfield 
notes, that study found no changes in body weight during the 28-day duration, nor were there 
any statistically significant findings that users felt less hungry when taking the products. 
PX3-17 ¶¶29-30. Defendants admit it does not substante their claims. PX24-42(361-368).22 
Apart from the CAHS study, there are no other clinical trials or scholarly articles about the 
Roca Labs products. PX3-16 ¶¶27, 34; PX5-4(26:21-27:5). See also PX24-42(360) (CAHS 
trial was the first and only non-observational trial of the products). 
 Dr. Heymsfield also reviewed and opined on other material about fiber either cited by 
Defendants or found in the scientific literature. He reviewed more than 100 peer-reviewed 
published scientific articles on weight loss and individual dietary fibers, and more than 15 
unpublished “research summaries” provided by Roca Labs about their “regimen” and 
                                                 
22 Defendants told their expert that no trials had been conducted on the Roca Labs products. PX5-4 
(26:21-27:5). 
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ingredients.23 PX3-5 ¶8. Based on his review, Dr. Heymsfield offered his expert opinion that 
the literature on weight loss and individual dietary fibers, as well as the research summaries 
provided by Roca Labs, do not provide competent and reliable scientific evidence for any of 
the Roca Labs claims. PX3-10 ¶¶11-12; PX3-31 ¶¶55-63. Defendants’ expert agrees. PX5-6, 
14 (35:11-19; 150:7-16) (no evidence for claim that product itself can “cause that type of 
weight loss” or that products force people to consume fewer calories than they expend). 
Juravin asserted in his interrogatory answer that at least six medical doctors advised 
Roca Labs, but Defendants only produced advice or recommendations from one, Ross 
Finesmith, a former physician who appeared in videos and wrote material for the websites. 
Finesmith, however, had no special experience with weight loss or obesity patients, and 
never told Juravin that he did. PX11-5(17:22-19:6); PX11-20(136:23-137:1). He did not 
conduct a clinical trial on the Roca Labs products, did not investigate the products, and did 
not investigate the truth of the Roca Labs claims. PX24-34(281-82, 294-298); PX11-7(30:12-
31:18). Much of his knowledge about how the products supposedly functioned came from 
Juravin. PX24-36(304-05, 332, 334); PX11-8(42:3-21); PX11-13(91:25-92:8); PX11-
15(102:2-23, 110:2-111:1).24  
                                                 
23 These research summaries were provided by, and in many cases co-authored by, Juravin, who is not 
a physician or scientist and has no expertise in obesity treatment and weight loss. PX24-52(394); 
PX6-71(391:12-20). Defendants’ expert testified that the summaries did not constitute credible 
scientific evidence. PX5-4(25:23-26:9). Defendants admitted that they do not establish that the Roca 
Labs ingredients or regimen are effective at causing substantial weight loss. PX24-43(369-380). 
 
24 Finesmith never told Juravin what he thought the product could accomplish in terms of weight loss. 
PX24-129(354). He also never advised Juravin that there was support for the challenged claims. 
PX24-129(355-59). Defendants admit that the articles Finesmith contributed to their website do not 
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Defendants asserted that they relied on the personal experiences of Juravin and Roca 
Labs customers. However, both Dr. Heymsfield and Defendants’ expert opine that anecdotal 
reports, such as user testimonials, are not reliable scientific evidence of the products’ effect, 
no matter how numerous or superlative. PX3-16 ¶¶ 25-26; PX5-14 (150:18-24).  
 Indeed, Juravin was well-aware that the Formula would not “physically [occupy] your 
stomach, leaving only 20% available space for 10-16 hours,” as Defendants repeatedly 
advertised. He candidly testified that this is a falsehood he tells prospective customers, in the 
hope that he can trick them into fasting for sixteen hours a day and believing that his Formula 
helped more than drinking a few liters of water would have by itself.  
I need to make my fat customer, I need to make them fast 16 hours. I cannot 
be direct with them, and say, hey, you’re going to fast 16 hours. Just listening 
to that is scary. I have to trick the customer with love.  
 
* * * 
Q  Are you saying there’s scientific evidence that they would lose those 
pounds if they drank three liters [of water] without the formula? 
A  Yes. If they do the three liters on their own, they would lose. If they do 
exercise, they would lose. If they do the 16 hours on their own, they would 
lose. . . .  I put everything all together, including scaring them, that if they 
don’t succeed now, they will go to a surgery.  
 
PX7-18(543:8-12; 545:22-546:6). See also PX7-17(538:21-539:3; 539:18-540:1; 542:24-
544:5; 545:12-546:6). See also PX5-14(151:8-10) (fiber will only remain in the gut for two 
to three hours). Juravin’s “gastric bypass effect” is, in a word, a hoax. 
                                                                                                                                                       
 
provide competent and reliable scientific evidence for the Roca Labs claims. PX24-127(336-40); see 
also PX3-21 ¶¶36-54. 
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2. Defendants’ Endorsements Were Deceptive 
 Defendants’ endorsements were deceptive. They ran a fake “informational” website, 
purporting to educate consumers about gastric bypass surgery, but in reality promoting the 
Roca Labs products. In some of their videos, they used actors who had never used Roca Labs 
products, reading scripts written by Juravin and those working at his direction. PX10-8 
(37:18-39:1; 60:13-24; 60:25-62:13); PX6-63(223:6-24). Other videos featured testimonials 
from individuals who worked for the Defendants, but with no indication of this relationship. 
Defendants also generated blogs, forum posts, and Facebook comments. None of these 
endorsements disclosed that Roca Labs was behind them. PX24-22 (179-88); PX24-60 (492, 
507-15); PX24-87 (645-60); PX10-37 (227:9-228:2; 230:13-21); PX12-11 (135:1-8). 
3. Defendants’ Privacy Promise Was False 
 Defendants’ privacy promise was a sham. They collected highly personal information 
during the purchase process, expressly promising not to share it. But in direct contravention 
of their stated policy, RLI publicly disclosed qualification information in lawsuits against 
purchasers filed in 2014 and 2015, including their ages, weights, heights, the number of 
pounds they wanted to lose, and health conditions. PX24-33(269-73); PX6-30(74:2-77:10); 
PX6-230; PX6-31(77:16-78:10; 78:20-79:24); PX6-293; Dkt 6-3, PageID 341-42 ¶¶11-13; 
Dkt. 6-5, PageID 522-73; PX10-19(124:2-7; 125:8-20); PX10-129. Defendants also sent 
customers’ qualification form information, including weight, height, age, sex, and personal 
reasons for purchasing Roca Labs products, in communications to payment processors about 
many payment card disputes between 2013 and when this lawsuit was filed, and even 
afterwards. PX24-33(274-76); PX10-16(103:6-111:12); PX10-109, 111, 122; PX6-60 (204:7-
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15; 205:24-206:19; 207:10-18; 212:19-213:2; 208:18-209:13; 213:8-13; 209:20-210:7; 
211:6-17; 213:14-18; 213:19-214:23); PX6-835, 846, 848. Juravin had direct knowledge of 
and directed these activities. PX10-17(107:9-17; 110:5-12); PX6-60(205:4-8). He asserts that 
some of the information was not private, PX7-29(614:16-20), and that the customer 
“Declarations” are private, but necessary to share with the card processor. Id. (614:7-615:3). 
Defendants’ privacy promise, however, was clear and unqualified; it was also false. 
4. Defendants Deceptively Claimed That Consumers Agreed to a 
“Discount” in Exchange for Silence 
 
 Defendants’ ads prominently advertised the product at $480. According to 
Defendants, however, this steep price was in fact being offered as a “discount” in exchange 
for buyers’ supposed agreement not to make negative comments. Of course, consumers never 
“agreed” to this “discount”; they never even knew about it. PX12-7(30:9-18; 32:17-33:7); 
PX12-10(117:24-118:18); PX24-28(239); see also PX14 ¶8; PX15 ¶6; PX16 ¶5; PX17 ¶8; 
PX18 ¶12; PX19 ¶¶5, 11; Dkt. 6-15, PageID 874 ¶4. Defendants’ websites did not offer an 
option to buy any quantity of their products, even without health insurance, for $1,580, the 
supposed “full price.” Dkt. 6-3, PageID 338-40 ¶8; PageID 362,364; PX6-48(152:14-17; 
159:25–160:12); PX6-828; PX12-13(160:18-161:17); PX12-18. Defendants only disclosed 
the purported “full price” to potential purchasers in the Terms and Conditions on their 
website PX24-29(245), a lengthy, easily missed document, or after their purchase was 
shipped, at which point it was nonrefundable and any complaints were forbidden. Consumers 
never agreed to the so-called “discount,” which Defendants used as a ruse to threaten and 
intimidate unhappy consumers.  
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D. Defendants’ Unfair Gag Clause Practices Were Likely to Substantially 
Injure Consumers 
 
Defendants’ gag clause practices not only injured the purchasers threatened for 
expressing negative opinions; they adversely affect the information available to the public at 
large and distort the marketplace. Online reviews have become important sources of 
information on products and services. Because Defendants’ gag clause practices, in the form 
of the warnings, threats, and contracts described above, limit all negative commentary, they 
suppress even truthful reviews expressing facts and genuine opinions.  
Research on consumer-generated online reviews supports the conclusion that 
restricting consumers’ ability to share truthful, negative information in the marketplace, as 
Defendants’ gag clause practices do, is likely to cause substantial injury. In the unrebutted 
opinion of the FTC’s expert, Paul A. Pavlou, Ph.D.,25 these practices are likely to negatively 
impact consumer welfare. PX4-7, 11-12, ¶¶11, 17-20. Dr. Pavlou evaluated the likely impact 
that suppression of purchasers’ negative online reviews about Defendants and their products 
– resulting from the use of non-disparagement provisions and related threats and warnings – 
would have on the welfare of consumers who are likely to purchase those products. PX4-5 
¶¶8-10. Online reviews, including negative reviews, play an important informational role for 
consumers. PX4-8 ¶¶13-15. Manipulation of reviews, including their suppression, lowers 
                                                 
25 Dr. Pavlou is the Milton F. Stauffer Professor of Information Technology and Strategy at the Fox 
School of Business at Temple University, and the Fox School’s Chief Research Officer and Associate 
Dean of Research, Doctoral Programs, and Strategic Initiatives. He is an expert in the field of 
information systems, with particular expertise in electronic commerce and emphasis on the study of 
consumer-generated online reviews. PX4-3 ¶¶2-6. 
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their information value. PX4-10 ¶16.26 In Dr. Pavlou’s opinion, Defendants’ practices are 
likely to inflate consumers’ perceptions of the quality of Defendants and Roca Labs products, 
thus increasing consumers’ willingness to buy the products; and consumers are less likely to 
learn about previous purchasers’ problems with Defendants and Roca Labs products, thus 
encouraging consumers to buy inappropriate products. See PX4-7, 11-12 ¶¶11, 17-20. 
E. Defendants’ Common Enterprise Controlled by Juravin 
1. Corporate Defendants Are a Maze of Interrelated Companies 
There was no real distinction between the Corporate Defendants, which shared 
officers, business functions, and assets. Juravin and Whiting have been the only owners and 
officers of all five Corporate Defendants. PX13-5; PX9-40 (RLI), 48(ZCL), 57(RLN); PX6-
125, 131, 134 (MCO), PX6-857 (JI). Since 2009, practically all Roca Labs Formula sales to 
customers were made via bank card transactions, and most customer payments were sent to 
bank accounts of either RLI or RLN. PX6-21(29:15-31:13). Gross revenues from sales 
deposited into RLN accounts were attributed to RLI for tax purposes in 2014 and 2015. PX6-
22(39:3-40:1). MCO has also received money from customer card payments. PX6-24, 27 
(47:3-48:4; 64:15-65:13); PX24-53(406, 409-10). Gross revenues from sales deposited into 
MCO accounts in 2014 and 2015 were also reported on RLI’s tax returns. PX6-26(65:11-
67:19). At times in 2010 through 2014, RLI, RLN, and ZCL accounts were used to pay 
independent contractors working for the Roca Labs business. PX6-19(23:13-19).  
                                                 
26 Juravin recognizes that reviews that he broadly defined as “false” (see pp.15-16, above) are bad for 
his business. PX6-27(61:25-62:7). 
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ZCL was set up to hire independent contractors to work for RLI’s benefit. PX24-
7(25); PX7-4(418:10-419:10). RLI was ZCL’s only client. PX9-24(208:6-11); PX7-
7(433:12-24). However, ZCL was also used to pay for advertising expenditures and 
ingredients for the Roca Labs business. PX9-25(215:20-216:9; 218:16-25); PX9-29(230:15-
231:15); PX7-9(455:21-457:16). JI was created primarily as a vehicle to run advertising for 
Roca Labs products. PX24-54(413); PX7-14(476:12-477:1). During 2014 and 2015, all JI’s 
income came from either RLI, RLN, or MCO placing online ads. PX7-14(473:17-478:15). JI 
is currently registrant of the RocaLabs.com, Mini-Gastric-Bypass.me, and Gastricbypass.me 
domains. PX6-46(144:24-145:22). Google search ads and keywords stayed largely the same 
from 2009 onward, regardless of which Corporate Defendant received consumers’ payments 
or paid for advertising. PX6-73(398:4-399:15). 
2. Juravin Controlled the Corporate Defendants and Common Enterprise 
Juravin controlled virtually every aspect of the Corporate Defendants’ business, 
including advertising, websites, claim substantiation, expenditures, personnel, and lawsuits. 
PX24-9(45-58; 62-76; 78-80; 92); PX24-23(181; 195-202); PX24-34(279, 287-288); PX24-
37(313-18); PX24-40(343-44); PX9-20(135:24-25; 136:8-14) (Juravin was “in charge of 
everything”); PX6-45(137:5-23) (“anything that was on the site was my responsibility”). 
Notwithstanding Whiting’s role as owner and officer of RLI [PX24-7(10-11); PX23-6 
(10-11); PX9-4, 10(16:10-14; 50:4-8)], Juravin controlled RLI from 2009 through 2015, 
carried out its marketing activities since 2009, and was in charge of its day-to-day operations. 
PX24-6(4, 13-15); PX13-7; Dkt. 58 ¶11. At times he served as one of its officers. PX24-6(1-
2, 5). He solely controlled RLI’s main checking accounts. PX24-8(30-32); PX7-10(458:15-
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460:17). RLI bank statements were addressed to Juravin’s home. PX9-32(252:20-253:10); 
PX9-35(261:13-262:3). Juravin personally authorized credit card expenditures for online ads. 
PX7-10(457:17-458:11); PX24-9(43). For RLI, Juravin was personally responsible for 
virtually every operational aspect of the company, including substantiation, advertising, 
finances, customer complaints, and litigation. PX7-5(425:7-432:3).  
Whiting was also ZCL’s officer and owner, PX23-6(23-24); PX9-18(115:9-19), but 
Juravin was personally responsible for selecting who would be retained, how much they were 
paid, fund transfers, and check writing. PX7-6(432:15-433:11); PX24-9, 10(41-42; 60-61). 
ZCL bank statements were addressed to Juravin’s home. PX9-27(221:20-24). 
Despite some apparent uncertainty as to legal ownership of RLN, Juravin was 
responsible for everything relating to the marketing, sales, and expenditures for RLN. PX6-
18(9:4-10; 11:23-12:13); PX6-20(25:1-25); PX6-10(55:11-18); PX24-6, 8(7-8, 37-39). 
Juravin created RLN, and was RLN’s sole officer in 2013. PX7-10(460:19-25); PX24-6 (6). 
Whiting is currently denominated as RLN’s owner. PX23-5(7-8).  
Juravin incorporated JI, is its sole owner, its officer, and controls it. PX24-7, 54(20-
22, 411-412); PX7-13(472:5-17). He is the sole signatory on JI’s bank and credit card 
accounts. PX7-15(479:5-481:11). Juravin also incorporated MCO, and is its sole owner and 
officer. PX24-7(16-18); PX6-23(44:11-14). He controls MCO’s bank and credit card 
accounts. PX7-11(462:23-466:8). 
For all five corporate entities, Juravin liberally transferred funds back and forth 
between them, transferred substantial sums to himself, and often paid his personal expenses 
from the corporate accounts. PX9-30(240:9-242:20); PX9-32(249:1-252:15); PX9-34 
Case 8:15-cv-02231-MSS-TBM   Document 141   Filed 03/24/17   Page 33 of 53 PageID 2970
 27 
 
(258:10-259:23); PX9-36(266:1-267:13); PX9-37(269:7-18); PX24-11(74), PX24-53, 54 
(400-403, 418); PX8-3(44:3-48:18). Juravin personally received approximately $7 million 
from the Corporate Defendants from 2009 to 2015. PX24-53(399); PX7-11(446:24-450:2). 
Whiting’s role was more limited. He was a licensed CPA (through 2013). PX9-5 
(19:12-24). He and Juravin first became acquainted in 2009 and met multiple times in 2009 
and afterwards to discuss the business. PX9-6(25:9–27:22, 28:8–33:19). Whiting performed 
bookkeeping and tax preparation services for some or all of the Corporate Defendants based 
on information provided by Juravin. PX23-11(84-85); PX9-8(33:24–36:14), PX9-10(51:21–
52:2); PX9-13(63:19–72:16); PX9-17(78:2–79:25); PX9-19(118:5-9). He had exposure to 
other aspects of the business,27 but was substantially less involved with the activities at issue 
in this case. PX23-11(86-90); PX24-13(93-112). Whiting was paid for bookkeeping services 
and received $42,000 in director’s fees, but he received no other compensation or distribution 
from the Corporate Defendants. PX23-12(91-92). 
IV. The Material Facts Are Undisputed and the FTC Is Entitled to Judgment as a 
Matter of Law 
 
A. Summary Judgment Standard 
The “court shall grant summary judgment if the movant shows that there is no 
genuine dispute as to any material fact and the movant is entitled to judgment as a matter of 
law.” Fed. R. Civ. P. 56(a). “Where the record taken as a whole could not lead a rational trier 
                                                 
27 PX9-39(281:4–282:5) (photo on website); PX9-9(46:4-11) (generally how ad money would be 
spent); PX9-11(53:1–59:24) (saw product packaging operation in Juravin’s garage; visits to 
warehouse and manufacturing plant); PX9-28(225:3-227:12) (had a company credit card); PX24-
15(115); PX9-16, 38(74:7-9; 278:24-279:18 ) (received some consumer complaints); PX9-21(140:23-
141:9), PX9-67 (signed declaration used in litigation with complaint site). 
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of fact to find for the nonmoving party, there is no ‘genuine issue for trial,’” and summary 
judgment is appropriate. Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574, 
587 (1986). The movant bears the initial burden of “identifying those portions of ‘the 
pleadings, depositions, answers to interrogatories, and admissions on file, together with 
affidavits, if any,’ which it believes demonstrate the absence of a genuine issue of material 
fact.” Celotex Corp. v. Catrett, 477 U.S. 317, 323 (1986) (quoting former version of Fed. R. 
Civ. P. 56(c)); Norfolk S. Ry. Co. v. Groves, 586 F.3d 1273, 1277 (11th Cir. 2009). Once the 
moving party has demonstrated the absence of a factual issue, the opposing party must 
produce specific facts showing a genuine issue of fact for trial. Anderson v. Liberty Lobby, 
Inc., 477 U.S. 242, 256 (1986); Jeffery v. Sarasota White Sox, Inc., 64 F.3d 590, 593-94 
(11th Cir. 1995).   
B. Sections 5 and 12 of the FTC Act Prohibit Deceptive and Unfair Acts or 
Practices  
 
1. Deception Under Section 5  
Acts or practices are deceptive under Section 5 of the FTC Act, 15 U.S.C. § 45, if (1) 
there was a representation, (2) it is likely to mislead customers acting reasonably under the 
circumstances, and (3) it is material. FTC v. Tashman, 318 F.3d 1273, 1277 (11th Cir. 2003). 
Further, a claim is material if it “involves information that is important to consumers and, 
hence, likely to affect their choice of, or conduct regarding, a product.” FTC v. 
Cyberspace.com, 453 F.3d 1196, 1201 (9th Cir. 2006) (citations omitted). Express claims, 
deliberately-implied claims used to induce the purchase of a product, and claims that 
“significantly involve health” are presumed material. Kraft, Inc. v. FTC, 970 F.2d 311, 322 
(7th Cir. 1992); FTC v. SlimAmerica, 77 F. Supp. 2d 1263, 1272 (S.D. Fla. 1999). Material 
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misrepresentations or omissions constitute deceptive practices. Tashman, 318 F.3d at 1277; 
FTC v. Bay Area Bus. Council, 423 F.3d 627, 635 (7th Cir. 2005); FTC v. NPB Advert., Inc., 
No. 8:14-cv-1155, 2016 U.S. Dist. LEXIS 151840, at *4, *13 (M.D. Fla. Nov. 2, 2016); 
SlimAmerica, 77 F. Supp. 2d at 1272.  
 In determining whether an advertiser has made deceptive claims, a court must 
consider the overall net impression created by the advertisement, and whether consumers 
acting reasonably under the circumstances would interpret it to contain a particular message. 
FTC v. Nat’l Urological Grp., Inc., 645 F. Supp. 2d 1167, 1189 (N.D. Ga. 2008), aff’d, 356 
Fed. Appx. 358 (11th Cir. 2009) (“NUG”); FTC v. QT, 448 F. Supp. 2d 908, 957-58 (N.D. 
Ill. 2006), aff’d, 512 F.3d 858 (7th Cir. 2008).28  
2. False Advertising Under Section 12  
Section 12 of the FTC Act prohibits the dissemination of any false advertisement in 
or affecting commerce for the purpose of inducing, or which is likely to induce, the purchase 
of food, drugs, devices, services, or cosmetics. 15 U.S.C. §§ 52, 55.29 A false advertisement 
is one that is “misleading in a material respect.” 15 U.S.C. §§ 52, 55; FTC v. Pantron I 
Corp., 33 F.3d 1088, 1099 (9th Cir. 1994). Courts apply the same three-prong test to 
                                                 
28 Courts routinely determine the existence of express and implied claims on summary judgment 
motions, even where defendants argue that there are issues of fact as to whether they made the 
representations. See NUG, 645 F. Supp. 2d at 1189 (concluding that “the court is well-equipped to 
discern express claims or clear and conspicuous implied claims from the face of the advertisement”).  
 
29 For the purposes of Section 12 of the FTC Act, Roca Labs “Formula,” and “Anti-Cravings” are 
either “foods” or “drugs.” 15 U.S.C. § 52; 15 U.S.C. §§ 55(b) and (c). See, e.g., NUG, 645 F. Supp. 
2d at 1190 (weight-loss supplements); SlimAmerica, 77 F. Supp. 2d at 1266, 1272-73 (same). 
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determine if a party has disseminated a “false advertisement” as to determine if an ad is 
deceptive under Section 5. See NUG, 645 F. Supp. 2d at 1188-89; Kraft, 970 F.2d at 314. A 
violation of Section 12 is a deceptive act in violation of Section 5(a). 15 U.S.C. § 52(b). 
3. Unfairness Under Section 5 
 Section 5 of the FTC Act prohibits “unfair” acts or practices in commerce, i.e., those 
that “cause[] or [are] likely to cause substantial injury to consumers which is not reasonably 
avoidable by consumers themselves and not outweighed by countervailing benefits to 
consumers or to competition.” 15 U.S.C. § 45(n). A practice that “unreasonably creates or 
takes advantage of an obstacle to the free exercise of consumer decisionmaking” is unfair. 
FTC Policy Statement on Unfairness, appended to International Harvester Co., 104 F.T.C. 
949, 1074 (1984). This can include a seller’s use of, and threats to enforce, certain 
contractual provisions to create such obstacles.30   
C. Defendants’ Weight Loss and Success Rate Claims Are False and 
Deceptive (Counts I, II) 
 
Defendants’ advertising and websites made five express weight-loss claims that the 
record shows are false and deceptive. See Section III.A, above. The FTC may show that ad 
claims are deceptive on the basis that:  (1) the advertiser had no reasonable basis to assert the 
claims as true, or (2) the claims are false. Pantron I, 33 F.3d at 1096; QT, 448 F. Supp. 2d at 
958-59. False and unsubstantiated claims are inherently “likely to mislead” consumers, and 
                                                 
30 Cf. Credit Practices Rule, Statement of Basis and Purpose, 49 Fed. Reg. 7740, 7762-65, 7768-70 
(1984) (prohibiting as unfair the use of certain provisions frequently included in consumer credit 
contracts; creditor threats to enforce them were commonplace; substantial injury caused by practices 
that flowed from inclusion of provisions in contracts). 
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consumers have no obligation to doubt the veracity of express claims. Thompson Med. Co., 
104 F.T.C. 648, 788, 818-19 (1984), aff’d, 791 F.2d 189 (D.C. Cir. 1986). For health-related 
efficacy claims, including weight-loss claims, an advertiser must possess “competent and 
reliable scientific evidence” to have a reasonable basis to assert a claim as true. NPB Adver., 
2016 U.S. Dist. LEXIS 151840, at *4; NUG, 645 F. Supp. 2d at 1190; QT, 448 F. Supp. 2d at 
961. The FTC’s expert Dr. Heymsfield notes that for weight-loss claims, in the relevant 
scientific community, competent and reliable scientific evidence means randomized, double-
blind, placebo-controlled human clinical trials on the product itself.31 See Section III.C.1, 
above. If a claim suggests that a product’s effectiveness or superiority has been scientifically 
established or proven, the advertiser must have evidence sufficient to satisfy the relevant 
scientific community of the claim’s truth. See POM Wonderful, LLC v. FTC, 777 F.3d 478, 
491 (D.C. Cir. 2015); FTC v. Coorga Nutraceuticals Corp., No. 2:15-cv-72, 2016 U.S. Dist. 
LEXIS 118308, at *11-12 (D. Wy. Aug. 15, 2016). Dr. Heymsfield states that these 
“scientific proof” claims about weight loss also would require such clinical trials. 
 As discussed above, there are no such clinical studies on Roca Labs products, and no 
studies that support the rapid and sustained weight loss that Defendants promise. Nor is there 
any evidence comparing the results of Defendants’ products to bariatric surgery, or 
evaluating their safety and efficacy for children. Indeed, it is simply false to say that the 
weight loss and success rate claims are “scientifically proven,” since there are no studies 
                                                 
31 QT, 512 F.3d at 862 (FTC Act lacks an exception for “beneficial deceit.” “Since the placebo effect 
can be obtained from sugar pills, charging $200 for a device that is represented as a miracle cure but 
works no better than a dummy pill is a form of fraud.”); Pantron I, 33 F.3d at 1097 (unlawful for 
seller to represent product as “effective” when its efficacy results solely from a placebo effect). 
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supporting them. These claims, which were express and involve health, are presumptively 
material. It is unlikely that consumers would spend nearly $500 on Roca Labs products if 
Defendants had not made these extreme claims, promising significant weight loss where all 
other attempts had failed, and promoting their products as a viable alternative to invasive and 
potentially dangerous surgery. That these ads generated more than $25 million in sales over 
five years, Section III.B, above, confirms their importance to consumers. 
D. Defendants’ Deceptive Representations and Omissions About 
Gastricbypass.me and Testimonialists (Counts IV, V) 
 
 Defendants misrepresented that Gastricbypass.me is an independent, objective 
resource for research and information related to bariatric surgery and alternatives to bariatric 
surgery for weight loss, and about Roca Labs products. See Section III.C.2, above. They 
failed to disclose that they own this website and were reviewing their own products. 
Defendants also failed to disclose, or failed to disclose adequately, their financial ties to some 
of their testimonialists and to agents who posted positive blogs and comments about 
Defendants’ products. Consumers would reasonably rely to their detriment on these material 
misrepresentations and omissions about the objectivity of the information presented because 
they would be unable to give appropriate weight or credibility to the representations. Thus, 
Defendants’ conduct is deceptive. See FTC v. Standard Educ. Soc’y, 302 U.S. 112, 118 
(1937) (use of fictitious testimonials to sell encyclopedias violated Section 5); see generally, 
16 C.F.R. § 255.5 (FTC guidance that material connections between seller and endorser that 
the audience may not reasonably expect must be fully disclosed). 
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E. Defendants’ Deceptive Privacy Promises (Count VI) 
Defendants also misrepresent that they keep private health information confidential. 
See Section III.C.3, above. In lawsuits filed against purchasers for violating the gag clause, 
however, Defendants’ court filings have published sensitive details from purchaser 
“qualification” responses. Similarly, in disputes over chargebacks, Defendants disclosed to 
payment processors the sensitive personal information ages, weights, heights, and sometimes 
purchasers’ reasons why they needed and had the proper commitment level to buy the 
products, including some of the very personal responses from consumers expressing why 
they needed to lose weight. Indeed, Juravin continued these practices even after this Court’s 
Preliminary Injunction (Dkt. 38, PageID 1574) forbidding him from engaging in them.  
These actions blatantly violate Defendants’ express privacy promise to the purchasers 
who reasonably entrusted them with private health information. Defendants’ express privacy 
promises are false or misleading, and are presumed to be material, and their conduct is 
therefore deceptive under Section 5 of the FTC Act. See FTC v. Five-Star Auto Club, Inc., 97 
F. Supp.2d 502, 528 (S.D.N.Y. 2000) (“Consumer reliance on express claims is 
presumptively reasonable.”); cf. FTC v. Para-Link Int’l, Inc., 2001 U.S. Dist. LEXIS 17372, 
*13 (M.D. Fla. 2001) (preliminary injunction against sellers of paralegal training 
opportunities; material misrepresentations or omissions made to induce purchase of goods or 
services constitute deceptive acts or practices that violate Section 5(a)).32 
                                                 
32 The FTC has taken action against companies that misrepresented their privacy practices, which  
resulted in settlements. See, e.g., Facebook, Inc., FTC Dkt. No. C-4365 (2012), 
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F. Defendants’ Deceptive Representation That Consumers Agree to Pay 
“Full Price” for Breach of Terms (Count VII) 
 
Defendants misrepresented that customers had agreed to pay hundreds of dollars 
more than what they actually paid, should they post negative reviews about the products or 
Defendants. After customers had purchased, Defendants told them in package inserts and 
threatening letters that they had agreed to a “subsidized” price, and to pay the difference 
between that price and a fictitious “full price” of $1,580 if they posted negative comments. In 
fact, purchasers agreed to no such thing. See Section III.C.4, above. 
The only pre-sale disclosure of this purported subsidy-for-silence agreement was in 
the Terms and Conditions. But consumers never had to read the Terms to buy the products. 
Defendants heavily advertised a $480 price, and consumers were offered options to pay 
$480, or perhaps a few hundred dollars more for installments, larger quantities, “premium” 
support, or other reasons. See, e.g., Dkt.6-2, PageID 248. A condition hidden in the fine print 
of the Terms cannot change or contradict the clearly advertised prices and conditions of 
purchase. See FTC v. Commerce Planet, 878 F. Supp. 2d 1048, 1065 (C.D. Cal. 2012) 
(disclosure of continuity program in separate hyperlinked “Terms of Membership” did not 
overcome net impression that product was free), aff’d in part and rev’d on other grounds, 
                                                                                                                                                       
 
https://www.ftc.gov/sites/default/files/documents/cases/2012/08/120810facebookdo.pdf (consent 
order) (settling charges that website misrepresented that users could restrict profile information to 
specific groups); Educational Rsch. Ctr. of Am., Inc., FTC Dkt. No. C-4079 (2003), 
https://www.ftc.gov/sites/default/files/documents/cases/2003/05/ercado.pdf (consent order) (settling 
charges that survey firm promised to share personal information it collected from students only with 
educational institutions, but also shared it with commercial entities for marketing).  
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815 F.3d 593 (9th Cir. 2016); see also Cyberspace.com, 453 F.3d at 1200-01 (small-print 
disclosures regarding a monthly fee not sufficient to defeat net impression that a check was a 
refund or rebate). Moreover, having to pay over $1,000 extra for the ability to post a negative 
comment obviously would have been material to consumers and served as a giant red flag to 
many of them. Thus, Defendants’ representations in post-purchase package inserts and letters 
that consumers had agreed to a subsidy-for-silence purchase condition are deceptive. 
G. Defendants Are Liable for Unfair Gag Clause Practices 
 Defendants’ use of gag clauses, including notices, threats, and lawsuits to prevent 
their customers from making truthful negative comments about them or their products, 
thwarts informed consumer decisionmaking and is unfair under Section 5.33  
1. Defendants’ Practices Cause or Are Likely To Cause Substantial 
Injury 
 
 Defendants’ gag clause practices cause or are likely to cause substantial injury by 
limiting the flow of truthful information about their products to consumers and the 
marketplace. Online reviews by consumers who have actually used a product or dealt with a 
seller can be an important source of information for prospective purchasers. Negative 
information from purchasers can be important to prospective customers because sellers have 
                                                 
33 Section 5(n) of the FTC Act states that public policy considerations can be considered, along with 
other evidence, in determining whether a practice is unfair. Enacted in December 2016, after the FTC 
filed this case, the Consumer Review Fairness Act invalidates and prohibits businesses from offering 
form agreements that restrict individuals’ right to review the business or its products. P.L. 114-258, 
Section 2(b)(1) and 2(c). Although not in effect during the time the challenged conduct occurred, the 
prohibitions in this new federal statute indicate that public policy, in addition to the other evidence in 
this case, supports the FTC’s contention that Defendants’ use of gag clauses is unfair. 
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little interest in disseminating negative, truthful criticism of themselves. Defendants gag 
purchasers to deprive prospective purchasers of potentially important information about the 
efficacy, tolerability, and side effects of Roca Labs products and about Defendants’ policies 
and practices. Consequently, purchasers will have spent, or will likely spend, significant 
sums of money and forgo or delay more effective weight-loss measures. The research on 
consumer-generated online reviews that Dr. Pavlou discussed in his report (PX4) supports 
the conclusion that restricting consumers’ ability to share truthful, negative information in 
the marketplace is likely to cause substantial injury. See Section III.A.5, above. 
Negative information would be especially useful for prospective Roca Labs 
purchasers in light of Defendants’ numerous deceptions. By depriving prospective purchasers 
of truthful, critical customer reviews about their products and practices, Defendants’ gag 
clause practices enable them to reduce the harm to their reputation even after they continually 
misrepresent the effectiveness of their goods. They have therefore likely been able to make 
sales they would not have otherwise made, and charge their customers higher prices than 
they might have otherwise.34   
Defendants recognize that negative reviews undercut their carefully crafted marketing 
campaign of promoting only positive information. They devoted significant resources to 
suing a review website for allegedly inducing breaches of the gag clause, PX6-29(70:1-11); 
                                                 
34 Cf. Statement of Basis and Purpose, Advertising of Ophthalmic Goods and Services, 43 Fed. Reg. 
23,992, 24,001 (1978) (“[E]conomic theory indicates that if price information is not available, or if it 
can be obtained only at high cost, consumers are deprived of the opportunity to satisfy their needs at 
the lowest available price. . . .  [T]he lack of price information means that in many places prices will 
be higher than they would be if consumers could readily compare potential sources of supply.”). 
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PX6-136, PX6-195, suing purchasers for allegedly breaching it; threatening other purchasers 
for saying that they will complain publicly; and warning all purchasers post-sale via package 
inserts that they are contractually bound not to make negative comments. These actions, on 
their face, evidence that any leakage of negative purchaser information into the marketplace 
harms Defendants’ business by reducing the volume of product that they can deceptively sell 
at a premium. They clearly believe that (and behave as if) negative purchaser comments 
cause, or are likely to cause, other consumers to doubt their deceptive claims, and thus be 
dissuaded from buying Defendants’ products. 
Similar restrictions prohibiting dissemination of truthful information by businesses 
aimed at competitors have been recognized to unfairly harm competition and consumers, 
including restraints on the dissemination of truthful information about products and services 
that relate to consumer health.35 The FTC has also long recognized that agreements between 
competitors to restrict truthful comparative advertising, including truthful criticism of 
competitors, harms competition in the marketplace.36 The FTC has challenged and prohibited 
these types of restrictions in numerous cases. See, e.g., Polygram Holding, Inc., 136 F.T.C. 
310, 354-55 (2003) (agreement between record companies barring truthful advertising of 
                                                 
35 Statement of Basis and Purpose, Advertising of Ophthalmic Goods and Services, 43 Fed. Reg. 
23,992, 24,007 (1978) (enacting 16 C.F.R. § 456.6(a)) (declaring it an unfair act or practice for 
private persons to prohibit, limit, or burden the dissemination of information concerning opthalmic 
goods and services by any seller). 
 
36 Statement of Policy Regarding Comparative Advertising, 16 C.F.R. § 14.15(c)(1) (truthful, non-
deceptive advertising that disparages a seller’s competitors, or their goods and services, is lawful; 
industry codes prohibiting such truthful advertising are subject to challenge by the Commission).   
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recordings not part of their joint venture held “presumptively anticompetitive”), aff’d, 416 
F.3d 29, 37 (D.C. Cir. 2005); RealComp II, Ltd., 2009 FTC LEXIS 250, *55-56, 70-73 
(F.T.C. Oct. 30, 2009) (agreement to restrict availability of real estate listings consumers use 
to evaluate competing providers’ offerings held “inherently suspect” and “presumptively 
unreasonable” where it made information more difficult to obtain and tended to alleviate 
downward pricing pressure), aff’d on other grounds, 635 F.3d 815 (6th Cir. 2011).   
2. Not Reasonably Avoidable by Consumers  
 Defendants’ gag clause practices cause injuries that are not reasonably avoidable by 
consumers.  Defendants’ prospective customers have no input into whether negative 
information about Defendants and their products is suppressed. Moreover, Defendants make 
it difficult for consumers to find and understand the gag clause. Prospective customers 
searching for information on Roca Labs or similar products would not necessarily know that 
previous purchasers had negative experiences. As the FTC stated in its Unfairness Policy 
Statement, “[i]t has long been recognized that certain types of sales techniques may prevent 
consumers from effectively making their own decisions. . . . Some [sellers] may withhold or 
fail to generate critical price or performance data, for example, leaving buyers with 
insufficient information for informed comparisons.” 104 F.T.C. at 1074. Defendants’ gag 
clause keeps a great deal of negative information from buyers, and makes it difficult or 
impossible for them to make a truly informed choice. 
3. Substantial Injury Not Outweighed by Countervailing Benefits 
 The injury from Defendants’ gag clause practices is not outweighed by countervailing 
benefits to competition or consumers. These practices do not protect any legitimate interest 
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of either Defendants or the consumers “agreeing” to it. Defendants’ practices, like the 
competitor advertising restrictions described above, are designed to insulate them from free 
competition with sellers of other weight-loss products and services. Defendants cannot state a 
legally cognizable, plausible competitive justification for their gag clause practices. Instead, 
they essentially admit that the purpose of the gag clause is to put an entirely (and 
misleadingly) positive spin on their products and enhance their bottom line: “Roca relies 
upon its reputation and the weight-loss success of its customers to generate new business and 
attract new customers. To foster, encourage, and protect its customer relationship, Roca has 
developed a special incentive / discount program, where it rewards customers for positive 
reviews and to refrain from making any negative postings.” PX6-199. These gag clause 
practices are “injurious in [their] net effects,” “prevent consumers from effectively making 
their own decisions,” and “undermine[] an essential precondition to . . . free and informed 
consumer transaction[s].” Unfairness Policy Statement, 104 F.T.C. at 1073, 1074. They are, 
therefore, unfair. Id. 
H. Juravin Is Individually Liable for Injunctive and Equitable Monetary 
Relief 
 
The FTC’s evidence establishes that the Corporate Defendants violated Sections 5(a) 
and 12 of the FTC Act. Once corporate liability is established, individual defendants may be 
held personally liable for the company’s violations if they (1) “participated directly in the 
practices or acts or had authority to control them,” and (2) “had some knowledge of the 
practices.” FTC v. Amy Travel Serv., Inc., 875 F.2d 564, 573 (7th Cir. 1989); FTC v. Gem 
Merch. Corp., 87 F.3d 466, 470 (11th Cir. 1996). In determining whether an individual 
defendant had the authority to control the company’s unlawful practices, the court looks to 
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the individual’s exercise of control over the practices in question. See Amy Travel, 875 F.2d 
at 573. The FTC can show control through evidence that an individual “controlled the day-to-
day affairs” of an operation. Gem Merch., 87 F.3d at 467.37 An individual’s “degree of 
participation in business affairs is probative of knowledge.” Amy Travel, 875 F.2d at 574. An 
individual is liable for equitable monetary relief if he “had actual knowledge of material 
misrepresentations, reckless indifference to the truth or falsity of such representations, or an 
awareness of a high probability of fraud along with an intentional avoidance of the truth.” Id. 
at 574. The FTC need not prove subjective intent to defraud. Id. at 573-74.  
Juravin directed every aspect of the Roca Labs business. He either participated 
directly in the deceptive acts or practices or had authority to control them. He also possessed 
the requisite knowledge to warrant liability for monetary relief. Juravin was extensively 
involved with the day-to-day operations of the companies, including financial and business 
dealings. He reviewed and/or approved the advertising and website content. He directed the 
many deceptive and unfair practices challenged here, including the deceptive endorsements, 
the release of personal information, and threats and lawsuits against consumers. Finally, 
Juravin knew that the company had no science to support its advertising claims for the Roca 
Labs supplements. Juravin essentially admitted that the “10-16 hours” claim was false, that 
the Formula, in and of itself, does not contribute to users’ weight loss, and that any weight 
                                                 
37 Probative evidence of an individual’s authority to control a company’s unlawful practices includes 
the authority to hire and fire personnel, FTC v. Atlantex Assocs., No. 87-0045-CIV, 1987 WL 20384, 
at *11-12 (S.D. Fla. Nov. 25, 1987), aff’d, 872 F.2d 966 (11th Cir. 1989), the authority to write 
checks and authorize payments, FTC v. Kitco of Nev., 612 F. Supp. 1282, 1293 (D. Minn. 1985), and 
the authority to write, review, and/or approve advertising, FTC v. Med. Billers Network, Inc., 543 F. 
Supp. 2d 283, 319 (S.D.N.Y. 2008). 
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loss they achieve is the result of their fasting to reduce their caloric intake, consumption of 
water, and exercise. PX7-17(538:21-539:3; 539:18-540:1; 542:24-544:5; 545:12-546:6). 
Juravin is thus individually liable for equitably monetary relief. 
I. Whiting Is Individually Liable for Injunctive Relief 
Whiting’s roles as owner and an officer of RLI, ZCL, and RLN gave him the 
authority to control the unlawful conduct alleged in this case. See FTC v. Freecom 
Commc’ns, Inc., 401 F.3d 1192, 1204-05 (10th Cir. 2005) (substantial inference that owner 
of closely held company had authority to control its deceptive practices); POM Wonderful, 
LLC v. FTC, 777 F.3d 478, 498-99 (D.C. Cir. 2015) (FTC required to show individual’s 
knowledge only when seeking equitable monetary relief.) (citations omitted). His 
participation also supports holding Whiting individually liable for injunctive relief. See FTC 
v. Ivy Capital, Inc., Civ. No. 2:11-283, 2013 WL 1224613, at *14 (D. Nev. Mar. 26, 2013) 
(participation can include working at and drawing salary from company, even if individual 
not involved day-to-day), aff’d, 616 Fed. Appx. 360 (9th Cir. 2015) (citations omitted). 
V. The Court Should Enter a Final Order with Injunctive Relief Against All 
Defendants, and Monetary Relief Against Juravin and the Corporate 
Defendants. 
 
This Court has the authority to grant permanent relief pursuant to Section 13(b) of the 
FTC Act, 15 U.S.C. § 53(b)), and to exercise its full equitable powers under Section 13(b) to 
remedy violations of Section 5. Gem Merch., 87 F.3d at 469-70; FTC v. U.S. Oil & Gas 
Corp., 748 F.2d 1431, 1433 (11th Cir. 1984); FTC v. Transnet Wireless Corp., 506 F. Supp. 
2d 1247, 1271-73 (S.D. Fla. 2007). The FTC may seek, and the district courts may grant 
“permanent injunctions against practices that violate any of the laws enforced by the 
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Commission.” Gem Merch., 87 F.3d at 468. The power to grant ancillary equitable relief 
under Section 13(b) includes the power to order monetary relief for consumer redress 
through repayment of money, restitution, rescission, or disgorgement of unjust enrichment. 
FTC v. Lalonde, 545 F. App’x 825, 841 (11th Cir. 2013); FTC v. Febre, 128 F.3d 530, 534 
(7th Cir. 1997). 
A. Permanent Injunctive Relief 
Injunctive relief against Defendants is appropriate where, as here, there is a risk that 
harm will recur. See United States v. W.T. Grant Co., 345 U.S. 629, 633 (1953) (court’s 
power to grant injunctive relief survives discontinuance of the illegal conduct; purpose of an 
injunction is to prevent future violations.). Juravin’s knowledge that key representations to 
consumers were false, his misuse of the legal system to intimidate his adversaries (see Dkt. 
126, PageID 2319), and his willingness to ignore or circumvent the limits of the preliminary 
injunction (see Dkt.69) demonstrate the risk that he will violate the law again if not enjoined. 
Moreover, while moving away from the Roca Labs brand, he is still selling the same 
products under the name “Gastric.care.” He markets via Facebook pages that he and MCO 
staff curate. PX6-68(367:7-368:2); PX6-70(386:24-387:23); PX7-22, 23, 25(558:7-559:2, 
572:23-582:19, 597:9-20). He fancies his current marketing as “Don’s Boot Camp,” where 
he uses “a lot of psychology” (in which he lacks formal training, PX7-20(550:4-16), and 
states with “a lot of confidence” what he previously “implied”: “[I]f you come here, if you 
want to work with me, if you want my regimen, I’m allowed to tell you anything I want; to 
do anything I want with you that would lead you to a healthy weight; anything.” PX7-18 
(541:1-548:25). Same snake oil; new bottle. Whiting, although less involved, was a corporate 
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owner and officer for years and let Juravin use his companies to carry out these deceptive and 
unfair acts. Injunctive relief is appropriate against all Defendants. 
B. Monetary Relief 
Monetary remedies, including consumer redress and disgorgement, are available to 
the Court to remedy Section 5 violations. See Gem Merch., 87 F.3d at 470; Transnet, 506 F. 
Supp. 2d at 1271. The proper measure of disgorgement is the amount of the defendants’ 
unjust gains. FTC v. Washington Data Resources, 704 F.3d 1323, 1326 (11th Cir. 2013). 
Gross receipts minus refunds is the method of calculating unjust gains. Id. at 1327. In 
determining unjust gains, this Circuit and other courts have consistently held that it is 
inappropriate to deduct costs associated with committing illegal acts. See, e.g., id. at 1327 
(upholding monetary award based on gross receipts rather than net profits); FTC v. Bronson 
Partners, LLC, 654 F.3d 359, 375 (2d Cir. 2011) (same).  
When one or more business entities operate as part of a common enterprise, each may 
be held liable for the deceptive acts and practices of the others under the FTC Act. See FTC 
v. Washington Data Resources, 856 F. Supp. 2d 1247, 1271 (M.D. Fla. 2012), aff’d, 704 F. 
3d 1323 (11th Cir. 2012); see also NUG, 645 F. Supp. 2d at 1182. Factors that determine the 
existence of a common enterprise include (1) common control; (2) shared office space; (3) 
whether the business is transacted through a maze of interrelated companies; and (4) 
commingling of funds. See, e.g., FTC v. LoanPointe, LLC, No. 10-CV-225, 2011 WL 
4348304, at *10 (D. Utah Sept. 16, 2011), aff’d, 525 F. App’x 696 (10th Cir. 2013). The 
undisputed evidence shows that in this case, Juravin led a common enterprise whose gross 
receipts minus refunds equals at a minimum $25,246,000. PX24-16(125-27, 129); PX9-
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23(169:9-171:3); PX6-4(14:21-15:9); PX6-7(34:9-36:23). The Court should find the 
Corporate Defendants and Juravin jointly and severally liable for that amount. 
VI. The FTC Proposes Appropriate Permanent Equitable Relief to Remedy 
Defendants’ FTC Act Violations. 
 
Upon request, the FTC is prepared to provide a proposed order with permanent 
injunctive and monetary relief. The injunctive relief would prohibit false or unsubstantiated 
health and non-health related claims about products or programs, including, but not limited 
to, the dietary supplements challenged in this case. Courts have confirmed the FTC’s 
authority to obtain broad injunctive relief covering products and claims similar to the product 
at issue and the challenged claims, when an advertiser has violated the FTC Act. See, e.g., 
FTC v. Colgate-Palmolive Co., 380 U.S. 374, 395 (1965) (“The Commission is not limited to 
prohibiting the illegal practices in the precise form in which it is found to have existed in the 
past.”); Kraft, Inc., 970 F.2d at 326 (multiproduct orders, known as “fencing-in,” are 
intended to prevent violators from engaging in similar deceptive practices in the future); 
SlimAmerica, 77 F. Supp. 2d at 1275 (“Broad injunctive provisions are often necessary to 
prevent transgressors from violating the law in a new guise.”) (citation omitted).  
The proposed order would prohibit deceptive endorsements, privacy promises, and 
subsidy-for-silence claims like those challenged here. It would prohibit unfair use of gag 
clauses and related threats, including retaliation against witnesses who complained to or 
cooperated with the FTC. The proposed order would also require Juravin and the Corporate 
Defendants to pay $25,246,000, equal to consumer sales minus refunds. See Wash. Data, 704 
F.3d at 1327. Finally, the proposed order has provisions to aid enforceability. Courts have 
included such provisions to ensure compliance with permanent injunctions in FTC cases. See, 
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e.g., FTC v. Sharp, 782 F. Supp. 1445, 1456-57 (D. Nev. 1991) (judgment included 
monitoring provisions); Think Achievement, 144 F. Supp. 2d at 1018 (ordering record 
retention, notification of changed employment or residence, access to premises, and 
monitoring); FTC v. Career Assist. Planning, Inc., No. 96-cv-2187, U.S. Dist. LEXIS 17191, 
at *13 (N.D. Ga. Sept. 18, 1997) (Commission monitoring to ensure adequate compliance); 
Transnet, 506 F. Supp. 2d at 1274 (requiring order distribution).  
VII. CONCLUSION 
No genuine issue of material fact remains in dispute. The Court should enter 
summary judgment for the FTC, impose injunctive relief to prevent future violations of the 
FTC Act, and order Corporate Defendants and Juravin to pay equitable monetary relief.  
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